IPO News Archive

1 IPO planned for the week of Feb 22

2/21/10


Anthera Pharmaceuticals, which is developing anti-inflammatory therapies for acute coronary syndrome and lupus, plans to raise $64 million by offering 4.6 million shares at a price range of $13-$15. At the mid-point of the proposed range, Anthera Pharmaceuticals will command a market value of $242 million. Anthera, which was founded in 2004, has yet to generate product revenue and is currently set to launch a Phase 3 trial for its lead drug candidate. The Hayward, CA-based company plans to list on the NASDAQ under the symbol ANTH. Deutsche Bank is the lead underwriter on the deal, which is expected to price this Tuesday, Feb. 23.

View IPO Profile: ANTH         
Related Links: Upcoming IPOs
Source: www.RenaissanceCapital.com
Latest User Comments
will this get done? 2/26/2010 11:40:31 AM
Posted by: Opul
Thoughts on Anthera actually pricing their IPO? Now it''s pushed into next week. Although there has been some other biotech activity - two new deals added to the calendar for later in March....
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest